Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

From the plant

CBGPCannabigerophorol

Heptyl (C7) homologue of CBG; only its acid has been reported, putatively, in the plant.

Unscheduled
Level of detail

C₂₃H₃₆O₂

CID 156493897

Family
PhytocannabinoidMinor
Origin
Tentative identification
Molar mass
344.53 g/mol

Updated on

In plain terms

CBGP is a CBG whose side chain has seven carbons instead of five. Its presence in cannabis has not been demonstrated: only its acid form has been detected there, without confirmation. It has only been studied in the laboratory and in mice, in synthetic form.

Receptors and activity

    Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

    Measured effects

    Not characterised. No placebo-controlled human trial has measured the effects of CBGP, so no level is shown.

    Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

    Pharmacology

    Cannabigerophorol (CBGP) is the heptyl (C7) homologue of cannabigerol: the same geranylated resorcinol, without a pyran ring, but with a seven-carbon side chain instead of five. Its existence in the plant is not established: only its presumed acid, CBGPA, has been putatively identified by UHPLC-HRMS in cannabis samples, without a reference standard (Linciano et al. 2021), and neutral CBGP has not been reported there. No affinity constant has been published. Synthetic CBGP was tested alongside other CBG homologues: in male mice made hypersensitive by cisplatin, 10 mg/kg intraperitoneally reduced mechanical hypersensitivity like the other homologues, and at 10 µM it did not significantly change the viability of seven colorectal cancer cell lines (Raup-Konsavage et al. 2022). No human, pharmacokinetic or toxicology data have been published.

    Key sources.

    History

    Source
    Origin not established. Only its presumed acid, CBGPA, has been reported in the plant, through a putative UHPLC-HRMS identification without a reference standard (Linciano et al. 2021); the presence of neutral CBGP in cannabis has not been reported.

    Biosynthetic pathway

    No formation pathway has been demonstrated for CBGP or for its presumed acid, CBGPA.

    Classification

    Family, origin and source verification

    Family

    Phytocannabinoid › Minor

    Presence in the plant

    Tentative identification, never isolated

    Chemistry

    Type CBG · C7 side chain · neutral form

    Verification

    Every fact on this entry was checked against its primary sources on 20 October 2026.

    Wikipedia (English)

    No dedicated article.

    References

    1. Linciano P. et al., heptyl phorolic cannabinoid content in different Cannabis sativa L. accessions (presumptive identification of CBGPA), Talanta 2021, 235:122704 (new tab)PMID 34517579
    2. Citti C. et al., discovery of Δ9-THCP and CBDP (« phorol » series), Sci Rep 2019, 9:20335 (new tab)PMID 31889124
    3. Raup-Konsavage W. M. et al., synthesis of CBG homologues (including CBGP) and effects in a mouse model of chemotherapy-induced neuropathy and on colorectal cancer cell lines, Biomolecules 2022, 12:1869 (new tab)PMID 36551296
    4. PubChem CID 156493897: cannabigerophorol (identifiers) (new tab)
    5. ANSM, consolidated list of substances classified as narcotics (26/06/2026) (new tab)

    Identifiers

    Names

    Common name
    Cannabigerophorol
    IUPAC name
    2-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-heptylbenzene-1,3-diol
    Other names
    CBG-C7 · CBGP

    Identifiers

    Formula
    C₂₃H₃₆O₂
    PubChem CID
    156493897(new tab)
    InChIKey
    DAOBMYOFOPZVGI-XMHGGMMESA-N
    SMILES
    CCCCCCCC1=CC(=C(C(=C1)O)C/C=C(\C)/CCC=C(C)C)O

    Machine-readable entry (JSON)

    LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.